Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones

22 Mar 2017

• By Mandy Jackson, Ian Haydock, Anju Ghangurde, and Joseph Haas

Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.

Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones

More from Business

More from Scrip